Report Details:
15 Companies Covered
153 Pages
Increasing Productivity in the Personalized Medicine Area to Fuel the Formulation Development Outsourcing Market Development at a CAGR of 8.10% through 2035
Formulation Development Outsourcing Market Overview
The global formulation development outsourcing market is witnessing substantial growth, driven by increasing R&D activities and the expanding number of pharmaceutical and biopharmaceutical companies outsourcing their formulation services.
The market is projected to grow from USD 10.8 billion in 2025 to USD 23.57 billion by 2035, registering a CAGR of 8.12% during the forecast period. The demand surge for generics and biosimilars, particularly following patent expirations, has been a major contributor to this expansion.
In 2024, the market was valued at USD 9.99 billion, underscoring a strong momentum toward outsourcing as companies seek to reduce costs, enhance development speed, and meet stringent regulatory requirements.
The increasing complexity of drug formulations and the need for cost-effective, high-quality solutions are further propelling this market.
Segment Insights
Based on services, the market is divided into pre-formulation services and formulation optimization. The formulation optimization segment held the majority share in 2022, as formulation outsourcing is integral at every stage of clinical development.
However, pre-formulation services are expected to witness faster growth, supported by the rising number of clinical studies, over 362,000 registered by 2021.
By dosage form, the market includes injectable, oral, topical, inhaled, and others. The oral segment dominated the market in 2022, driven by its convenience and wide application in treating common diseases such as diabetes and infections.
The injectable category, however, is anticipated to be the fastest-growing due to its superior bioavailability and immediate onset of action.
In terms of application, oncology led the market in 2022 and is expected to continue its dominance, supported by the growing number of cancer-related clinical trials. Over 29,000 active studies for cancer were registered as of June 2022, increasing demand for formulation development outsourcing in oncology therapies.
The respiratory segment is projected to grow rapidly owing to rising incidences of respiratory conditions.
By end user, academic institutes accounted for the largest revenue share in 2022 due to escalating R&D costs. The pharmaceutical and biopharmaceutical segment is anticipated to be the fastest-growing, reflecting the sector’s rising reliance on outsourcing for efficiency and innovation.
Regional Insights
Regionally, North America dominated the formulation development outsourcing market, accounting for USD 3.61 billion in 2022 with a 45.80% share. The region’s growth is supported by a strong base of pharmaceutical innovators, an increasing prevalence of chronic diseases, and the presence of major market players in the US.
Europe held the second-largest market share, bolstered by a large number of cost-effective contract research organizations (CROs). The UK was the leading contributor, while Germany emerged as the fastest-growing market in the region.
The Asia-Pacific market is expected to record the highest CAGR through 2035, driven by strategic government initiatives and rising R&D investments.
Notably, India’s Department of Pharmaceuticals drafted new policies in 2021 to halve product approval timelines, encouraging growth in outsourcing services. Within the region, China led the market share, while India was the fastest-growing market.
Key Players
Prominent players in the global formulation development outsourcing market include Charles River Laboratories (US), Laboratory Corporation of America (US), Intertek (US), Catalent Inc. (US), Lonza Group AG (Switzerland), Syngene International Limited (India), Aizant Drug Research Solutions Pvt. Ltd. (US), and Dr. Reddy’s Laboratories (India).
These companies are investing significantly in research, expanding service portfolios, and adopting strategic initiatives such as partnerships, mergers, and capacity expansions to strengthen their global presence.
The increasing emphasis on regulatory compliance, technological advancement, and quality assurance continues to shape competition in this sector.
Industry Developments
- The industry has seen multiple strategic developments in recent years. In Q2 2024, Catalent opened a new formulation development facility in Kansas City, enhancing oral and injectable capabilities.
- In Q1 2024, Thermo Fisher Scientific acquired a CDMO for USD 1.7 billion, expanding its service offerings.
- Lonza entered a multi-year partnership with BioNTech for mRNA formulation development in Q2 2024 and later announced a USD 100 million investment in a new Swiss facility in Q1 2025.
- Other notable activities include Pfizer’s inauguration of a new development center in Ireland (Q3 2024), Recipharm’s acquisition of Arranta Bio (Q2 2024), Samsung Biologics’ expansion of formulation facilities (Q3 2024), and WuXi AppTec securing a major European contract (Q2 2025).
Key Findings
- The formulation development outsourcing market was valued at USD 9.99 billion in 2024 and is expected to reach USD 23.57 billion by 2035, growing at a CAGR of 8.12%.
- Oncology remains the leading application area, while injectable dosage forms exhibit the fastest growth.
- North America dominated with a market share of 45.8%, with Asia-Pacific showing the highest future potential.
- Growing demand for biosimilars, patent expirations, cost optimization, and technological advances such as AI-driven formulation development are key forces shaping this market’s evolution.
